Fosmanogepix
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Feb 1, 2023 (NCT05421858)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 3 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06925321 | Phase 3 | Aug 26, 2025 | Basilea Pharmaceutica, Department of Health and Human Services |
| NCT05421858 | Phase 3 | Feb 1, 2023 | Pfizer |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Basilea Pharmaceutica | For profit | 1 | 1 | 1 | 2025 |
| Department of Health and Human Services | Government | 1 | 0 | 1 | 2025 |
| Pfizer | For profit | 1 | 1 | 1 | 2023 |
3 organizations
Page 1 / 1